Urogen Pharma Ltd (URGN)

08:38 AM

Tick level data insight on UroGen Pharma Ltd. volatilityJuly 2025 Momentum & Verified Momentum Watchlists - newser.com

08:38 AM

05:37 AM

Is UroGen Pharma Ltd. stock bottoming out2025 Big Picture & Growth Oriented Trade Recommendations - newser.com

05:37 AM

02:58 AM

Why UroGen Pharma Ltd. (UR8) stock trades below fair valueTrade Risk Assessment & High Win Rate Trade Alerts - newser.com

02:58 AM

02:07 AM

How UroGen Pharma Ltd. stock compares to industry benchmarks2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com

02:07 AM

Oct 12, 2025

Using AI based signals to follow UroGen Pharma Ltd.Long Setup & Fast Exit/Entry Strategy Plans - newser.com

Oct 12, 2025

Oct 11, 2025

Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛

Oct 11, 2025

Oct 11, 2025

Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN - MarketBeat

Oct 11, 2025

Oct 11, 2025

What technical models suggest about UroGen Pharma Ltd.’s comebackJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com

Oct 11, 2025

Oct 10, 2025

Chris Degnan Sells 2,203 Shares of Urogen Pharma (NASDAQ:URGN) Stock - MarketBeat

Oct 10, 2025

Oct 10, 2025

Understanding UroGen Pharma Ltd.’s price movementEarnings Beat & Safe Swing Trade Setups - newser.com

Oct 10, 2025

Oct 10, 2025

Is UroGen Pharma Ltd. reversing from oversold territoryJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com

Oct 10, 2025

Oct 10, 2025

Is UroGen Pharma Ltd. (UR8) stock a momentum leaderJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat

Oct 09, 2025

Oct 09, 2025

UroGen Pharma CFO Degnan sells $37k in shares By Investing.com - Investing.com UK

Oct 09, 2025

Oct 09, 2025

UroGen Pharma CFO Degnan sells $37k in shares - Investing.com

Oct 09, 2025

Oct 09, 2025

Is UroGen Pharma Ltd. (UR8) stock worth holding before Fed meeting2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com

Oct 09, 2025

Oct 07, 2025

UroGen continues to climb after bladder cancer drug approval - MSN

Oct 07, 2025

Oct 07, 2025

UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - Sahm

Oct 07, 2025

Oct 05, 2025

Is UroGen Pharma Ltd a good long term investmentVolatility Index Analysis & Consistent Triple Returns - earlytimes.in

Oct 05, 2025

Oct 05, 2025

UroGen Pharma Ltd. stock outlook for YEARPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com

Oct 05, 2025

Oct 05, 2025

How to recover losses in UroGen Pharma Ltd. stock2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com

Oct 05, 2025

Oct 05, 2025

Can swing trading help recover from UroGen Pharma Ltd. lossesJobs Report & High Accuracy Swing Entry Alerts - newser.com

Oct 05, 2025

Oct 03, 2025

NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com

Oct 03, 2025

Oct 03, 2025

UroGen Pharma (URGN): Maintained Buy Rating by D. Boral Capital | URGN Stock News - GuruFocus

Oct 03, 2025

Oct 03, 2025

Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Oct 03, 2025

Oct 03, 2025

Why UroGen Pharma Ltd. (UR8) stock stays on buy listsMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com

Oct 03, 2025

Oct 03, 2025

UroGen’s bladder cancer treatment shows durable response in clinical trials By Investing.com - Investing.com Nigeria

Oct 03, 2025

Oct 03, 2025

Can machine learning forecast UroGen Pharma Ltd. recoveryAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com

Oct 03, 2025

Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ - GlobeNewswire

Oct 02, 2025

Oct 02, 2025

Can IL FS Transportation Networks Limited Deliver Margin Expansion Amid InflationEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in

Oct 02, 2025

Oct 02, 2025

What drives UroGen Pharma Ltd stock priceStock Market Trends & Smart Beta Strategies That Actually Work - earlytimes.in

Oct 02, 2025

Oct 02, 2025

URGN: UroGen Pharma's ZUSDURI Shows Promising Results for Bladder Cancer - GuruFocus

Oct 02, 2025

Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times

Oct 02, 2025

Oct 02, 2025

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewswire

Oct 02, 2025

Oct 02, 2025

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 02, 2025

Oct 01, 2025

Urogen Pharma (NASDAQ:URGN) Trading Down 5.9%Here's Why - MarketBeat

Oct 01, 2025

Oct 01, 2025

UroGen Pharma Hits Day High with 15.59% Surge, Outperforming S&P 500 - Markets Mojo

Oct 01, 2025